Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)
NCT00567060 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)
- Lead sponsor
- UCB Pharma
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- May 31, 2000
- Completion date
- January 31, 2004
- Enrollment
- 676 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.